A bulk-lyophilized sodium salt of low molecular weight heparin (LMWH) obtained by oxidative-depolymerization of Heparin Sodium. Anti-Factor Xa activity:≥70 IU/mg; Mean MW 5,500 Da.
A water-insoluble benzalkonium salt of Heparin Sodium that is essentially free of sodium. Assay: > 65 u/mg; Benzalkonium: 0.9 - 1.1%. Benzalkonium Heparin Solution [BY-3189] or H-Bac is a 1.5% solution of Benzalkonium Heparin [HB-3185] in Isopropyl Alcohol USP. Assay: 700.900 u/ml; Benzalkonium: 0.9 - 1.1%.
A water-soluble, bulk-lyophilized, heparin derivative with high amine content produced by selective partial de-N-sulfation. Anti-Factor Xa activity: 70-90 IU/mg; Residual amino groups: > Δ 15 μmol/g.
A water-soluble, bulk-lyophilized sodium salt of dermatan sulfate obtained from crude heparin of porcine tissue. DS-0312 reflects a typical dermatan monosulfate containing only L-iduronic acid residues and a D-galactosamine residue which is fully 4-O-sulfated. Optical rotation: ≤ - 50°; Heparin assay: ≤ 1 u/mg.
A proprietary, water-soluble, bulk-lyophilized sodium salt of repeating L-iduronic acid → 4,6-O-disulfated N-acetyl-D-galactosamine disaccharide units. Assay: ≥ 70 IU/mg heparin cofactor II-mediated anti-Factor IIa activity.
A bulk-lyophilized LMWH obtained by ß-eliminative cleavage of Heparin Sodium Benzyl Ester (HE-3825) that is biosimilar to the active pharmaceutical ingredient in Enoxaparin Sodium Injection. Anti-Factor Xa activity: 90-125 IU/mg; Average MW: 3800.5000 Da.
A water-soluble, bulk-lyophilized fraction of crude heparin of porcine mucosal tissue comprising primarily ΔUA → GlcNAc (≈ 75%) that is resistant to degradation by heparin lyase I, consistent with its being heparan sulfate. Optical rotation: ≥50°; Heparin assay: < 5 u/mg; Ave MW: ≈ 15 kDa.
A water-soluble, bulk-lyophilized, ammonium salt of heparin obtained by cation exchange chromatography.
A sodium salt of a heparin derivative obtained by the esterification of a quaternary heparin. Degree of esterification: ≈ 13%.
A water-soluble, bulk-lyophilized, calcium salt of heparin that meets the compendial specifications of the European and United States pharmacopoeias. Assay: ≥ 150 u/mg; Calcium: 9.5-11.5%.
An affinity ligand structurally modified to introduce reactive aldehyde groups at the reducing end for end-point attachment with the hydrazide groups on the beaded matrix to form hydrozone bonds. Ligand immobilized: 10-15 mg/ml; Binding capacity: > 10 human AT/ml.
A water-soluble, bulk-lyophilized, lithium salt of heparin obtained by cation exchange chromatography. Assay: > 160 u/mg; Lithium: 3.5 - 4.5%
A water-soluble, bulk-lyophilized, sodium salt of heparin that meets the compendial specifications of the European, Japanese and United States pharmacopoeias. Assay: ≥ 160 u/mg; Sodium: 9.5 - 12.5%;
A water-soluble, bulk-lyophilized, zinc-lithium salt of heparin obtained by cation exchange chromatography. Assay: > 150 u/mg; Zinc: 7.0 - 10.0%.
A derivative of crude heparin comprising the sodium salt of naturally-occurring polyanions, typically comprising at least 55% of fast-moving heparin fractions, 20- 35% of dermatan sulfate, and < 5% of chondroitin sulfate.
A water-soluble, bulk-lyophilized, heparin derivative manufactured by controlled periodate-oxidation. Assay: > 100 u/mg; Aldehydes: 0.36 - 0.68 @ 655 nm.
A water-insoluble stearyldimethylbenzylammonium salt of heparin. Assay: ≥ 50 u/mg; Stearalkonium: 60-70%,